 | Up a level |
Catapano, A; Reiner, Z; De Backer, G; Graham, I; Taskinen, M; Wiklund, O; Agewall, S; Alegria, E; Chapman, M; Durrington, P; Erdine, S; Halcox, J; Hobbs, R; Kjekshus, J; Filardi, P; Riccardi, G; Storey, R; Wood, D; incl. Windecker S, (2011). Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis, 217(1), pp. 3-46. Amsterdam: Elsevier 10.1016/j.atherosclerosis.2011.06.028
Marre, M; Shaw, J; Brändle, M; Bebakar, WM; Kamaruddin, NA; Strand, J; Zdravkovic, M; Le, Thi TD; Colagiuri, S; De Loredo, L; Waitman, J; Litwak, L; Rodriguez, M; Vines, G; Maffei, L; Issa, C; Lowy, A; Bartley, P; Kamp, M; Shaw, J; ... (2009). Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabetic medicine, 2009(26(3)), pp. 268-78. Chichester: Wiley 10.1111/j.1464-5491.2009.02666.x
